Atogepant

Atogepant
Clinical data
Trade names	Qulipta
Other names	AGN-241689, MK-8031
License data	US DailyMed: Atogepant;
Routes of; administration	By mouth
ATC code	N02CD07 (WHO) ;
Legal status
Legal status	US: ℞-only [1];
Identifiers
	IUPAC name (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide;
CAS Number	1374248-81-3;
PubChem CID	72163100;
DrugBank	DB16098;
ChemSpider	59718640;
UNII	7CRV8RR151;
KEGG	D11313;
ChEMBL	ChEMBL3991065;
Chemical and physical data
Formula	C29H23F6N5O3
Molar mass	603.525 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F;
	InChI InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1; Key:QIVUCLWGARAQIO-OLIXTKCUSA-N;

Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.[1][2]

It was approved for medical use in the United States in September 2021.[1][3]

Medical uses

Atogepant is indicated for the preventive treatment of episodic migraine in adults.[1]

A study found that atogepant reduced the number of migraine days over twelve weeks.[4]

"Qulipta- atogepant tablet". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (June 2020). "Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?". Current Opinion in Neurology. 33 (3): 309–315. doi:10.1097/WCO.0000000000000806. PMID 32251023. S2CID 215408433.
"FDA Approves Qulipta (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine". AbbVie (Press release). 28 September 2021. Archived from the original on 28 September 2021. Retrieved 29 September 2021 – via PR Newswire.
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. (August 2021). "Atogepant for the Preventive Treatment of Migraine". The New England Journal of Medicine. 385 (8): 695–706. doi:10.1056/NEJMoa2035908. PMID 34407343.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.